Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The study, which tested the drug in 529 patients with obesity and heart failure with preserved ejection fraction (HFpEF), demonstrated a 16.6-point increase at 52 weeks, with regard to the Clinical Summary Score (CSS) on the Kansas City Cardiomyopathy Questionnaire (KCCQ) a measure of symptoms of heart failure in comparison to an 8.7-point increase in the placebo group
As your body adjusts to the medication, it may cause temporary changes in how it regulates temperature, leading to sensations of heat or sweating
This is the situation in which a permanent solution becomes worth considering
N-acetyltransferase SNPs: emerging concepts serve as the paradigm for understanding complexities of personalized medicine
10.1016/j.cell.2016.05.041 Cell
Genetic studies of body mass index yield new insights for obesity biology
US$ 20.22
US$ 27.92
US$ 20.27
US$ 26.21
US$ 22.77
US$ 21.75
US$ 21.60
